Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01391585 · ClinicalTrials.gov registry record · NA
Expanding Comparative Effectiveness Research (CER) Capability Through Complex Patient Relationship Management
A NA study of Diabetes and Hyperlipidemia, sponsored by Denver Health and Hospital Authority.
- Completed
- Registry status
- NA
- Development phase
- 135
- Enrollment target
- 1
- Study location
NCT01391585: Completed NA study of Diabetes and Hyperlipidemia, sponsored by Denver Health and Hospital Authority.
NCT01391585 is a NA study of Diabetes and Hyperlipidemia that has completed, run by Denver Health and Hospital Authority. The registered enrollment target is 135 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01391585, a NA study of Diabetes and Hyperlipidemia, has completed, sponsored by Denver Health and Hospital Authority.
- COMPLETED
- Registry status
- NA
- Development phase
- 135 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators are testing whether patients with diabetes can communicate with our health care system through text messaging. The investigators will look at how often they respond to prompts for blood pressures, blood sugars, and step counts. The investigators will also see if they come in for lab tests when prompted by text message. Also, for patients overdue for medication refills, the investigators will ask them why they have not yet called for the refill.
Primary Outcome
resonse rate to blood pressure, blood sugar, and step count prompts
Conditions Studied
Interventions
- OTHER Text Message prompts
Study Locations (1)
Colorado
- Denver Health - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-08 |
| Phase | NA |
What the finished NCT01391585 record still lists
NCT01391585 is an interventional study that assigns participants to a tested intervention. The registered 135 participants enrollment target is mid-sized for trials with a published cap, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Text Message prompts is the first listed.
NCT01391585 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT01391585 about?
NCT01391585 is a clinical study titled "Expanding Comparative Effectiveness Research (CER) Capability Through Complex Patient Relationship Management". The investigators are testing whether patients with diabetes can communicate with our health care system through text messaging. The investigators will look at how often they respond to prompts for blood pressures, blood sugars, and step counts. The investigators will also see if they come in for la...
What is the current status of trial NCT01391585?
This trial is currently completed. It is a NA study. The enrollment target is 135 participants. The study started on 2011-06. Estimated completion is 2012-08.
What conditions does trial NCT01391585 study?
This clinical trial studies the following conditions: Diabetes, Hyperlipidemia.
What interventions are being tested in trial NCT01391585?
The interventions under investigation include: Text Message prompts (OTHER).
Who is sponsoring clinical trial NCT01391585?
This trial is sponsored by Denver Health and Hospital Authority, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01391585 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01391585's enrollment target sits among peer trials
135 179th of 338 higher than 160 of 338 other Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
-
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
RECRUITING · NA
-
Bringing Advocacy Via Digital Guide to the Emergency Department (Project BADGE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00870129 · 135 participants · NA
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- NCT03666000 · 135 participants · Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04891510 · 135 participants · NA
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
- NCT05121051 · 135 participants · Phase 2
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia